Denali Therapeutics Inc. (DNLI) Key Metrics
DNLI valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $2.81B
- Enterprise value
- $2.59B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 781.1 10-yr median 30.2
- Price / book
- 3.9 10-yr median 3.4
- EV / EBITDA
- 86.5
- Dividend yield
- —
- Beta
- 1.02
DNLI key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDNLI valuation Price multiples at each fiscal year-end price.
Price / book+4.8%
2.9
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−3.7 pts
−14.6%
2025 · hover or tap a bar for each year
20162025
DNLI returns How much profit the business earns on the capital it uses.
Return on equity−8.3 pts
−45.7%
2025 · hover or tap a bar for each year
20162025
Return on invested capital+16.1 pts
−139.6%
2025 · hover or tap a bar for each year
20162025
Return on assets−7.2 pts
−40.7%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
DNLI per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$2.92
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$2.41
2025 · hover or tap a bar for each year
20162025
Book value per share−22.7%
$5.78
2025 · hover or tap a bar for each year
20162025
Shares outstanding+6.7%
175.5M
2025 · hover or tap a bar for each year
20162025
DNLI financial health Debt, liquidity and how easily interest is covered.
Debt / equity−8.5%
0.04
2025 · hover or tap a bar for each year
20162025
Net debt−$47.5M
−$831.1M
2025 · hover or tap a bar for each year
20162025
Current ratio+8.3%
9.16
2025 · hover or tap a bar for each year
20162025
Debt / assets−9.4%
0.03
2025 · hover or tap a bar for each year
20162025
DNLI efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−247 days
236 days
2025 · hover or tap a bar for each year
20162025
DNLI valuation history
Fiscal year-endToday10-year median
DNLI returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DNLI debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DNLI price vs earnings per share
Share price at year-endEPS (right axis)
DNLI key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.90B | $3.35B | $2.95B | $3.49B | $5.42B | $9.44B | $1.67B | $1.91B | — | — |
| Enterprise value | $2.07B | $2.57B | $1.97B | $2.22B | $4.62B | $8.04B | $1.32B | $1.47B | — | — |
| P/E ratio | — | — | — | — | — | 132.7 | — | — | — | — |
| Price / sales | — | — | 8.9 | 32.2 | 111.4 | 28.1 | 62.4 | 14.8 | — | — |
| Price / book | 2.9 | 2.7 | 2.9 | 3.3 | 5.6 | 8.2 | 4.2 | 3.5 | — | — |
| Price / free cash flow | — | — | — | — | — | 22.9 | — | 41.0 | — | — |
| Price / operating cash flow | — | — | — | — | — | 22.7 | — | 38.2 | — | — |
| EV / sales | — | — | 5.9 | 20.4 | 94.9 | 24.0 | 49.6 | 11.4 | — | — |
| EV / EBITDA | — | — | — | — | — | 112.8 | — | — | — | — |
| EV / free cash flow | — | — | — | — | — | 19.5 | — | 31.4 | — | — |
| Earnings yield | −17.7% | −12.6% | −4.9% | −9.3% | −5.4% | 0.8% | −11.9% | −1.9% | — | — |
| Free cash flow yield | −14.6% | −10.8% | −12.6% | −7.5% | −4.1% | 4.4% | −10.2% | 2.4% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $16.51 | $20.38 | $21.46 | $27.81 | $44.60 | $83.76 | $17.42 | $20.66 | $15.64 | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $2.41 | $0.86 | $0.40 | $2.98 | $0.28 | $1.39 | — | — |
| Earnings per share | −$2.92 | −$2.57 | −$1.06 | −$2.60 | −$2.39 | $0.63 | −$2.07 | −$0.39 | — | — |
| Operating cash flow per share | −$2.35 | −$2.11 | −$2.61 | −$1.95 | −$1.74 | $3.69 | −$1.59 | $0.54 | — | — |
| Free cash flow per share | −$2.41 | −$2.21 | −$2.70 | −$2.09 | −$1.81 | $3.67 | −$1.77 | $0.50 | — | — |
| Cash per share | $4.95 | $5.06 | $7.53 | $10.64 | $7.12 | $13.04 | $4.34 | $5.01 | — | — |
| Book value per share | $5.78 | $7.48 | $7.50 | $8.30 | $7.92 | $10.21 | $4.13 | $5.90 | — | — |
| Tangible book value per share | $5.78 | $7.48 | $7.50 | $8.30 | $7.92 | $10.21 | $4.13 | $5.90 | — | — |
| Capex per share | $0.05 | $0.10 | $0.09 | $0.14 | $0.07 | $0.03 | $0.19 | $0.04 | — | — |
| Debt per share | $0.21 | $0.30 | $0.38 | $0.48 | $0.53 | $0.61 | $0.76 | $0.21 | — | — |
| Shares outstanding | 175.5M | 164.5M | 137.4M | 125.5M | 121.5M | 112.7M | 95.6M | 92.6M | — | — |
| Change in shares outstanding | +6.7% | +19.7% | +9.4% | +3.3% | +7.8% | +17.9% | +3.2% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −45.7% | −37.4% | −14.0% | −32.5% | −27.5% | 9.2% | −42.0% | −7.2% | −24.5% | −72.5% |
| Return on invested capital (ROIC) | −139.6% | −155.6% | — | — | — | — | −219.1% | −45.4% | −104.9% | −463.4% |
| Return on assets (ROA) | −40.7% | −33.4% | −11.1% | −22.8% | −19.3% | 6.6% | −32.5% | −6.3% | −23.3% | −56.3% |
| Return on tangible assets | −44.8% | −30.8% | −12.6% | −22.3% | −20.7% | 4.4% | −35.7% | −5.5% | −18.1% | −32.0% |
| Free cash flow margin | — | — | −112.2% | −242.1% | −451.9% | 123.1% | −635.3% | 36.2% | — | — |
| Income quality (OCF / net income) | — | — | — | — | — | 5.85 | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $36.8M | $48.7M | $52.2M | $60.4M | $64.0M | $68.9M | $72.5M | $19.1M | — | — |
| Cash & short-term investments | $867.9M | $832.3M | $1.03B | $1.34B | $865.4M | $1.47B | $415.4M | $464.3M | $406.2M | $178.3M |
| Net debt | −$831.1M | −$783.6M | −$982.3M | −$1.28B | −$801.4M | −$1.40B | −$342.8M | −$445.2M | −$406.2M | −$178.3M |
| Debt / equity | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.06 | 0.18 | 0.03 | — | — |
| Debt / assets | 0.03 | 0.04 | 0.05 | 0.04 | 0.05 | 0.04 | 0.13 | 0.03 | — | — |
| Net debt / EBITDA | — | — | — | — | — | −19.66 | — | — | — | — |
| Current ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 | 9.48 | 14.67 | 28.92 | 19.98 |
| Quick ratio | 9.16 | 8.46 | 13.65 | 3.78 | 2.37 | 20.86 | 9.48 | 14.93 | 28.95 | 19.98 |
| Interest coverage | — | — | — | -23.1 | -22.4 | 3.5 | -14.0 | -23.7 | -46.1 | — |
| Working capital | $802.3M | $762.2M | $986.2M | $1.01B | $519.0M | $1.42B | $384.7M | $448.1M | $395.4M | $172.8M |
| Invested capital | $182.6M | $446.1M | $48.7M | −$233.4M | $160.9M | −$250.3M | $52.1M | $101.6M | $59.6M | $76.2M |
| Tangible asset value | $1.01B | $1.23B | $1.03B | $1.04B | $962.3M | $1.15B | $394.9M | $546.8M | $465.8M | $254.5M |
| Net current asset value | $769.6M | $719.9M | $941.2M | $954.5M | $455.4M | $1.04B | $271.7M | $365.7M | $388.7M | $165.4M |
| Graham number | — | — | — | — | — | $12.04 | — | — | — | — |
| Graham net-net per share | $4.21 | $4.19 | $6.65 | $7.35 | $3.49 | $9.05 | $2.69 | $3.79 | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | 0.0% | — | 0.0% | — | — |
| Capex / revenue | — | — | 3.9% | 16.4% | 17.5% | 0.9% | 67.2% | 2.6% | — | — |
| Capex / operating cash flow | — | — | — | — | — | 0.7% | — | 6.8% | — | — |
| Capex / depreciation | 0.64 | 1.77 | 0.77 | 1.72 | 0.99 | 0.36 | 2.24 | 0.46 | 0.93 | 4.18 |
| Stock-based compensation / revenue | — | — | 32.7% | 92.1% | 175.2% | 15.0% | 143.9% | 14.5% | — | — |
| R&D / revenue | — | — | 128.2% | 330.7% | 545.3% | 63.3% | 724.9% | 110.9% | — | — |
| SG&A / revenue | — | — | 31.3% | 83.4% | 162.5% | 18.0% | 174.2% | 25.0% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | 7.0 | 17.7 | 25.9 | 6.2 | — | 12.7 | — | — |
| Days of inventory on hand | — | — | -54.6 | -259.5 | — | — | — | -11.5 | -2.3 | — |
| Days payables outstanding | 236.1 | 482.8 | 133.9 | 196.4 | 190.3 | 3.1 | 4.2 | 5.9 | 11.5 | 456.7 |
| Cash conversion cycle (days) | — | — | -181.5 | -438.3 | -164.5 | 3.0 | — | -4.6 | — | — |
| Receivables turnover | 0.00 | 0.00 | 52.04 | 20.64 | 14.10 | 59.16 | — | 28.67 | 0.00 | 0.00 |
| Payables turnover | 1.55 | 0.76 | 2.73 | 1.86 | 1.92 | 116.15 | 86.31 | 62.16 | 31.83 | 0.80 |
| Asset turnover | 0.00 | 0.00 | 0.25 | 0.08 | 0.03 | 0.31 | 0.04 | 0.22 | 0.00 | 0.00 |
| Average receivables | $2.2M | $2.8M | $6.4M | $5.3M | $3.5M | $5.7M | — | $4.5M | $451,000 | $438,000 |
| Average payables | $7.2M | $10.3M | $6.1M | $3.8M | $2.9M | $1.8M | $2.2M | $2.3M | $2.3M | $1.8M |
| Average inventory | — | — | −$2.5M | −$5.0M | — | — | — | −$4.5M | −$464,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from DNLI's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DNLI valuation and financial ratios
Denali Therapeutics earned a return on equity of −45.7% and a return on invested capital of −139.6% in fiscal 2025. It ended the year with $36.8 million of debt and $867.9 million in cash and short-term investments, a net cash position of $831.1 million.
See the DNLI income statement, the DNLI chart for price history, or the DNLI stock overview for the latest quote and news.
DNLI key metrics FAQ
What is Denali Therapeutics's return on equity?
Denali Therapeutics's return on equity (ROE) was −45.7% in fiscal 2025: net income of -$512.5 million on average shareholders' equity of $1.1 billion.
What is Denali Therapeutics's ROIC?
Denali Therapeutics's return on invested capital was −139.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Denali Therapeutics have?
Denali Therapeutics had total debt of $36.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
What is Denali Therapeutics's free cash flow yield?
Denali Therapeutics generated -$422.1 million of free cash flow in fiscal 2025, a free cash flow yield of −14.6% on its market value at year-end ($2.9 billion).
What is Denali Therapeutics's current ratio?
Denali Therapeutics's current ratio was 9.16 at the end of fiscal 2025: current assets were 9.16 times current liabilities.